IDH2 and glioblastoma: Nevertheless, novel data define molecular subgroups of IDH-wildtype glioblastomas, including a telomerase-positive subgroup driven by TERT structural rearrangements and an ALT-positive subgroup with mutations in ATRX or SMARCAL1 which demonstrate poorer survival compared with IDH-mutant/TERT-wildtype GBMs [77].